The patients presenting with acute pulmonary embolism and right ventricular dysfunction are at high risk for life-threatening events and must be identified in the emergency department for adequate care and hospital admission. Echocardiography can identify right ventricular dysfunction, but this test is not always available, and echocardiographic criteria of right ventricular dysfunction vary among published studies. The primary purpose of this protocol is to study the prognostic value of a cardiac biomarker, h-FABP (heart-type Fatty Acid-Binding Protein) , to identify in the emergency department the patients presenting with high risk pulmonary embolism. As secondary outcomes, H-FABP results will be compared to other cardiac biomarkers (BNP, troponin) and clinical score performances that have been previously studied to stratify the prognosis of patients with pulmonary embolism in the emergency department.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
165
Dosage de l'h-FABP
Hôpital Rangueil Service des urgences
Toulouse, France
number of death by pulmonary embolism
Time frame: 1 month
life-threatening pulmonary embolism (cardiopulmonary arrest, shock, mechanical ventilation)
Time frame: 1 month
recurrent episode of pulmonary embolism
Time frame: 1 month
prognostic value of a clinical score (PESI), BNP and troponin in acute pulmonary embolism
Time frame: 1 month
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.